Evidence map›Paper›PMID 34683466›Full record

ArticleMicroorganisms2021

SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort.

Florian Laubscher, Samuel Cordey, Alex Friedlaender, Cecilia Schweblin, Sarah Noetzlin, Pierre-François Simand, Natacha Bordry, Filipe De Sousa, Fiona Pigny, Stephanie Baggio and 4 more

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Florian LaubscherLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
Samuel CordeyLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.ORCID 0000-0002-2684-5680
Alex FriedlaenderDepartment of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
Cecilia SchweblinLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
Sarah NoetzlinDepartment of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
Pierre-François SimandDepartment of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
Natacha BordryDepartment of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.ORCID 0000-0002-3523-438X
Filipe De SousaDepartment of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
Fiona PignyLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
Stephanie BaggioFaculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
Laurent GetazFaculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
Pierre-Yves DietrichFaculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
Laurent KaiserLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
Diem-Lan VuLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
University Hospital of Geneva · CHUniversity of Geneva · CH

Funding

Fondation de Bienfaisance du Groupe Pictet ME11710
6 · The paper itself

Abstract

backgroundOncological patients have a higher risk of prolonged SARS-CoV-2 shedding, which, in turn, can lead to evolutionary mutations and emergence of novel viral variants. The aim of this study was to analyze biological samples of a cohort of oncological patients by deep sequencing to detect any significant viral mutations.

methodsHigh-throughput sequencing was performed on selected samples from a SARS-CoV-2-positive oncological patient cohort. Analysis of variants and minority variants was performed using a validated bioinformatics pipeline.

resultsAmong 54 oncological patients, we analyzed 12 samples of 6 patients, either serial nasopharyngeal swab samples or samples from the upper and lower respiratory tracts, by high-throughput sequencing. We identified amino acid changes D614G and P4715L as well as mutations at nucleotide positions 241 and 3037 in all samples. There were no other significant mutations, but we observed intra-host evolution in some minority variants, mainly in the ORF1ab gene. There was no significant mutation identified in the spike region and no minority variants common to several hosts.

conclusionsThere was no major and rapid evolution of viral strains in this oncological patient cohort, but there was minority variant evolution, reflecting a dynamic pattern of quasi-species replication.

Indexed as

compartmenthigh-throughput sequencingminority variantsoncological patientsSARS-CoV-2

Identifiers

PMID34683466
PMCPMC8540785
OpenAlexW3206195578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.